

INFORMATION ONLY

Glassia Update

Customer Letter # 2024-11

2024-02-28

Dear Colleagues:

As shared in CL 2024-04, Glassia (alpha-1-proteinase inhibitor, [A1-PI]), manufactured by Takeda, will be available to be ordered from Canadian Blood Services on **February 29, 2024**. In Alberta, Glassia will be available through Bayshore Pharmacy on **March 18, 2024**.

Requesting and Ordering Glassia

As Glassia is listed on the PPRP formulary with eligibility criteria, the prescriber must submit a Request for Patient Designated Plasma Protein and Related Products form to Canadian Blood Services at SAPPRPRequests@blood.ca or to their local Canadian Blood Services distribution site to request access for their patients.

Glassia can be ordered from Canadian Blood Services using the patient's contract number through either the Online Ordering Portal or by completing the *Order Form for Plasma Protein and Related Products Requiring Contracts*.

Both the Request Form and Order Form have been updated to include Glassia. The revised forms are available on the <u>Submitting Product Orders</u> webpage under the appropriate distribution site.

Additional Information

A Frequently Asked Questions (FAQ) document has been created to answer questions about the implementation of Glassia and provide details on how to access it (see attached).

The FAQ document has sections pertaining to patients, clinics, clinicians and Transfusion Medicine Laboratories. There is also a separate section for Distribution Modernization which provides details on how to access Glassia in Alberta through Bayshore Pharmacy.

Hospital customers, clinical groups, and other stakeholders are all encouraged to circulate the FAQ widely. The content from the FAQ may also be used for the development of stakeholder notices or patient education tools.



Any questions regarding the patient support program (PSP) or administration of Glassia should be directed to the OnePath program:

• Email: support@onepathprogram.ca

• Tel: 1-844-691-7284

Please share a copy of this customer letter with healthcare professionals at your hospital who might be interested in this information.

This customer letter can also be viewed at www.blood.ca in the "Hospital Services" section. If you have questions about this letter, or if you require it in an accessible format, please contact your local hospital liaison specialist.

Sincerely,

Sylvain Grenier, Director, Plasma Protein and Related Products Formulary Program